R

Regeneron Pharmaceuticals

Develops biopharmaceutical therapies for serious diseases

AI/ML & Data Engineering Intern

Summer 2027Updated
$17.90 - $50.90/hr
Internship
Bachelor's, Master's
Cambridge, MA, USA+4 moreMore locations: Armonk, NY, USA | Warren, NJ, USA | Sleepy Hollow, NY, USA | Tarrytown, NY, USA
HybridMost positions are onsite; some are hybrid. Internship runs full-time from May/June through August.
AI & Machine LearningApplied Machine Learning

About the job

Requirements
  • Must be enrolled in, or accepted to, an academic program pursuing an undergraduate or graduate degree and be returning to school the semester following the position or graduating after the position.
  • Python, SQL, and software engineering fundamentals are typically expected, along with familiarity with large language model prompting or machine learning packages.
  • Relevant majors include Computer Science, Data Science, Statistics, Bioinformatics, Information Technology, Mathematics, and Biomedical Engineering.
Responsibilities
  • Build and test AI solutions used on real systems.
  • Work on projects that may include building AI agents and large language model-powered applications, mining text with natural language processing, building and modernizing data pipelines and semantic data models, evaluating and validating AI tools and models, and automating routine workflows with AI-assisted coding tools.
  • Perform hands-on software and data engineering, work with scientists and business teams to understand problems, and use AI responsibly and with appropriate governance.
Desired Qualifications
  • Demonstrated leadership in campus activities, clubs, sports, current or previous work, or the community.
  • A cumulative GPA of 3.0 or higher.

About the company

R

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops and commercializes medicines for serious diseases, with a focus on cancer, eye diseases, allergic and inflammatory diseases, and infectious diseases. Its products come from using proprietary research capabilities and technologies to discover and develop therapies, often in collaboration with academic, research, and industry partners. Revenue comes from selling approved medicines and from licensing its technologies and entering co-development and co-commercialization partnerships. The company works with healthcare providers and regulators to ensure treatment delivery and safety. Its goal is to improve patient outcomes by bringing life-transforming medicines to market through rigorous R&D and strategic collaborations, maintaining leadership in biopharmaceutical innovation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Mount Pleasant, New York

Founded

1988

Get referred to Regeneron Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi paid $1 billion upfront, with up to $7 billion more for Regeneron's immunology pipeline.
  • Q2 2026 revenue rose 17% to $4.3 billion; Dupixent sales hit $6.0 billion.
  • Libtayo and EYLEA HD both posted record sales in Q2 2026, widening diversification.

What critics are saying

  • EYLEA biosimilar competition starts in January 2027 after Samsung's settlement.
  • Regeneron faces a 2026 SDNY securities class action over the failed fianlimab melanoma trial.
  • Dupixent's patent cliff later this decade threatens the company's biggest profit pool.

What makes Regeneron Pharmaceuticals unique

  • VelocImmune keeps generating partnered immunology assets; Sanofi renewed the alliance on October 1, 2026.
  • Dupixent remains Regeneron's engine, with over 1.5 million patients across nine indications.
  • EYLEA HD conversion shows platform strength; U.S. sales hit $596 million in Q2 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Wellness Program
  • Paid Vacation
  • Equity Awards
  • Annual Bonuses
  • Flexible Work Hours

Growth & Insights and Company News

6 month growth

1%

1 year growth

12%

2 year growth

12%
Yahoo Finance
Oct 30th, 2026
Regeneron posts record Dupixent, EYLEA HD and Libtayo sales; eyes November FDA decision on cemdisiran

Regeneron Pharmaceuticals reported record quarterly net sales for Dupixent, EYLEA HD, and Libtayo in the third quarter of 2026. It was the third straight quarter of double-digit growth in both revenue and profit. EYLEA HD now makes up nearly two-thirds of the US retinal franchise, with physician demand up 20% sequentially. Libtayo's US sales rose 81%. Regeneron expects a US Food and Drug Administration decision in November on cemdisiran for generalized myasthenia gravis. It would be the first siRNA therapy for the condition. The company expects 2027 research and development spending to rise by a mid-teens percentage to support about 15 Phase 3 trials. It also signalled a shift towards acquiring outside innovation, from early-stage platforms to commercial-stage products. Third quarter Ilaris royalty revenue included a one-off catch-up of about $60 million.

Yahoo Finance
Oct 30th, 2026
Regeneron Q3 revenue jumps 36% to $5.1B as Dupixent and Eylea HD drive growth

Regeneron Pharmaceuticals reported third-quarter revenue of $5.1 billion, up 36% year over year. Non-GAAP diluted earnings per share rose 70% to $20.07, driven by higher Sanofi collaboration revenue and growth in DUPIXENT, EYLEA HD and LIBTAYO. DUPIXENT sold more than $6.5 billion worldwide. EYLEA HD sales rose 62% to $699 million, while legacy EYLEA fell 41% to $400 million amid biosimilar competition. LIBTAYO sales grew 51% to $550 million. The company expects a US Food and Drug Administration decision in November on cemdisiran for generalized myasthenia gravis. It plans more than 15 Phase III trial starts in 2026. Regeneron expects a $1 billion upfront payment from Sanofi in the fourth quarter. It ended the quarter with $16.2 billion in cash and marketable securities, net of debt.

Yahoo Finance
Oct 30th, 2026
Regeneron jumps 13.55% on Q3 earnings beat as revenue climbs 36% to $5.1B

Regeneron shares jumped 13.55% to $929.69 on October 30, 2026, after third-quarter results beat expectations. Non-GAAP earnings per share were $20.07 against a $16.19 consensus estimate, and revenue rose 36% year over year to $5.12 billion. Sanofi collaboration revenue climbed 68% to $2.72 billion. US sales of EYLEA HD rose 62% and Libtayo grew 51%, while the company raised its full-year non-GAAP gross margin guidance to about 86%. The rally lifted sector funds. The Health Care Select Sector SPDR Fund (XLV) gained 1.8% and the iShares Biotechnology ETF (IBB) rose 1.25%. Regeneron expects a US Food and Drug Administration decision on cemdisiran next month.

Yahoo Finance
Oct 30th, 2026
Regeneron Q3 revenue jumps 36% to $5.12B, beating estimates as EPS hits $20.07

Regeneron reported third-quarter revenue of $5.12 billion, up 36.3% from a year earlier and 12.43% above the Zacks Consensus Estimate of $4.55 billion. Earnings per share (EPS) were $20.07, against $11.83 a year ago and a consensus of $16.08. Collaboration revenue rose 52.4% to $3 billion, led by Sanofi at $2.72 billion, up 68.5%. Bayer revenue fell 22.6% to $267 million. Net product sales grew 13.7% to $1.81 billion. Kevzara sales jumped 66% to $255.6 million, while Praluent rose 21% to $260.9 million. Total Dupixent revenue was $6.54 billion, up 34.7%. Regeneron shares gained 11.4% over the past month, compared with 0.7% for the S&P 500 composite.

Yahoo Finance
Oct 30th, 2026
Regeneron shares jump 8% as Q3 revenue surges 36% to $5.12B, beating estimates

Regeneron Pharmaceuticals shares rose more than 8% in premarket trading on Friday after the biotech firm beat third-quarter estimates. If gains hold, the stock would reach its highest level since October 2024. Revenue rose 36% to $5.12 billion, above analyst estimates of $4.56 billion. Adjusted earnings per share climbed 70% to $20.07, against expectations of $16.25. US sales of Eylea HD, its higher-dose retinal disease treatment, rose 62% to $699 million, while sales of the original Eylea fell 41%. Collaboration revenue from Sanofi jumped 68% to $2.72 billion, driven by Dupixent demand. Chief financial officer Christopher Fenimore said the results position Regeneron to deliver "one of our strongest years ever." The company ended September with about $18.86 billion in cash and marketable securities.